Uncertainties and ethics

Trust is built on honesty. This appendix speaks openly about the limits of the treatment and of this book, about the ethical principles and the regulatory background — not to unsettle you, but to enable you to make well-founded, informed decisions together with your treating physician.

The strength of the evidence and its limits

The evidence for treating recurrent Clostridioides difficile infection with FMT is strong. Faecal microbiota transplantation is the recommended therapy for multiple recurrence in the international guidelines (IDSA/SHEA), and since the classic randomised trial (van Nood, 2013 [7]) numerous studies have confirmed the high cure rate compared with antibiotics. The capsule-based, orally administered form has proved equivalent in efficacy to colonoscopic delivery (Kao, 2017 [45]).

At the same time, we must say honestly: the long-term data are limited. FMT is a relatively young treatment method, and little data are available on follow-up over many years or many decades. Science is still actively researching the relationship between the gut flora, the immune system, and long-term health. This is not a reason for concern in the established indication (recurrent CDI), but it is a reason for the treatment always to be carried out consciously and under medical supervision.

The limits of the SIS and of decision support

The SIS (Symptom Severity Scale) featured in the book is an internal, decision-support tool that helps with the objective assessment of the severity of CDI and the selection of the appropriate preparation. It is important to know, however, that the SIS has not yet been prospectively validated — that is, the reliability of the scoring system has not yet been fully confirmed by forward-looking clinical studies. The SIS therefore never replaces the medical decision: it solely supports the treating physician's professional judgement, and is not suitable for automatic classification without medical review. The scale is currently valid only for adults and exclusively for C. difficile infection.

Regulatory status

The regulatory background of the DiffBiome service is as follows. The activity takes place within the framework of "Medical Laboratory Services (869015)", and the preparations fall into the category of substances of human origin (SoHO — Substances of Human Origin). The finalisation of the European Union classification is expected, as planned, towards the end of 2026. The treatment is in all cases tied to specialist medical supervision. From a legal standpoint, MicroBiome Bank does not provide a product but a service; the contents of the capsule are the property of the donor until the recipient pays. Adverse events must be reported within the framework of pharmacovigilance to the competent authorities (EMA/FDA/local authority).

Donor ethics and informed consent

FMT is based on the gift of another person — the donor. This carries a particular ethical responsibility on both sides. Donors are volunteers who undergo strict, multi-stage screening (twofold serological testing, multiplex PCR pathogen panel, exclusionary medical and lifestyle criteria), and who take part in the programme informed and with their consent given. On the recipient's side, informed consent is likewise the foundation: you have the right to understand what you are receiving, why, and with what risks, and you have the right to ask questions before you start. This book serves precisely that informedness.

What this book does not replace

Finally, the most important point: this book is an educational publication that supports self-management; it does not replace medical diagnosis, treatment, or personal medical advice. What it contains provides general information, but your situation is unique. Every treatment decision — starting the course, the dose, tapering, a repeat cycle — must be made together with your treating physician. If you notice a warning sign (red flag), do not read the book — turn to a doctor immediately. The book is your companion on the journey; your doctor is your guide.

References

[7] van Nood E, Vrieze A, Nieuwdorp M et al. Duodenal infusion of donor feces for recurrent Clostridium difficile. N Engl J Med. 2013. Link

Open-label RCT in patients with recurrent C. difficile infection comparing duodenal donor faeces infusion (after short vancomycin + bowel lavage) with standard 14-day vancomycin, with or without bowel lavage. The primary endpoint was diarrhoea resolution without relapse at 10 weeks. The trial was stopped early at interim analysis: 13/16 patients (81\%) in the FMT arm achieved resolution after a single infusion, substantially exceeding both vancomycin arms. Establishes FMT as superior to antibiotic monotherapy for recurrent CDI and provides the landmark evidence base for FMT clinical translation.

[45] Kao D, Roach B, Silva M et al. Effect of Oral Capsule– vs Colonoscopy-Delivered Fecal Microbiota Transplantation on Recurrent Clostridium difficile Infection: A Randomized Clinical Trial. JAMA. 2017. Link

Noninferiority randomized trial in 116 adults with recurrent CDI across three Canadian academic centres comparing oral capsule FMT with colonoscopy-delivered FMT (enrolment 2014–2016; noninferiority margin 15\%). The study tested whether less invasive capsule delivery matches colonoscopy in preventing further CDI recurrence. Results support clinical equivalence between routes, enabling broader and lower-burden access to FMT for recurrent CDI.